MS4A1 and diffuse large B-cell lymphoma: Lastly, the safety and effectiveness of tafasitamab and lenalidomide, in combination with plamotamab, an investigational bispecific antibody that targets CD20 and CD3, is being studied in patients with r/r DLBCL (NCT05328102).